Patient Characteristics
| Characteristic | EGFR+ | KRAS+ | Total |
| No. of patients | 44 | 96 | 348 |
| Sex | |||
| Male | 9 (20%) | 34 (35%) | 134 (39%) |
| Female | 35 (80%) | 63 (65%) | 214 (61%) |
| Age (y) | |||
| Median | 61 | 67 | 65 |
| Range | 34–88 | 46–84 | 34–93 |
| Ethnicity | |||
| Caucasian | 38 (86%) | 91 (95%) | 316 (91%) |
| African American | 2 (5%) | 4 (4%) | 21 (6%) |
| Hispanic | 2 (5%) | 1 (1%) | 4 (1%) |
| Asian | 2 (5%) | 0 (0%) | 6 (2%) |
| Not reported | 0 (0%) | 0 (0%) | 1 (0%) |
| Smoking history | |||
| Current/former | 24 (55%) | 93 (97%) | 286 (82%) |
| Never | 20 (45%) | 3 (3%) | 62 (18%) |
| Primary site | |||
| Upper lobe | 28 (64%) | 57 (59%) | 215 (62%) |
| Middle lobe | 1 (2%) | 12 (13%) | 27 (8%) |
| Lower lobe | 14 (32%) | 24 (25%) | 98 (28%) |
| Overlapping lesion | 1 (2%) | 1 (1%) | 2 (1%) |
| Clinical stage | |||
| I | 15 (34%) | 30 (31%) | 102 (29%) |
| II | 4 (9%) | 11 (11%) | 44 (13%) |
| III | 16 (36%) | 36 (38%) | 144 (42%) |
| IV | 9 (21%) | 19 (20%) | 58 (16%) |
| Tumor grade | |||
| Well differentiated | 4 (9%) | 8 (8%) | 32 (9%) |
| Moderately differentiated | 19 (43%) | 25 (26%) | 107 (31%) |
| Poorly differentiated | 13 (30%) | 36 (38%) | 126 (36%) |
| Not determined | 8 (18%) | 27 (28%) | 83 (24%) |
| Histology | |||
| Adenocarcinoma | 36 (82%) | 84 (88%) | 251 (72%) |
| Squamous cell carcinoma | 0 (0%) | 2 (2%) | 31 (9%) |
| Non–small cell lung carcinoma NOS | 7 (16%) | 10 (10%) | 60 (17%) |
| Other | 0 (0%) | 0 (0%) | 7 (2%) |
| No pathology report | 1 (2%) | 0 (0%) | 3 (1%) |
| PET/CT scanners | |||
| GE Discovery | |||
| ST | 13 (30%) | 21 (22%) | 81 (23%) |
| STE | 16 (36%) | 36 (37%) | 135 (39%) |
| LS | 2 (5%) | 3 (3%) | 12 (3%) |
| RX | 6 (14%) | 13 (14%) | 46 (13%) |
| Siemens Biograph | |||
| mCT | 5 (11%) | 15 (16%) | 43 (13%) |
| True Point | 1 (2%) | 3 (3%) | 9 (3%) |
| Phillips Gemini TF | 0 (0%) | 5 (5%) | 14 (4%) |
| Unspecified | 1 (2%) | 0 (0%) | 8 (2%) |
NOS = not otherwise specified.
Other histology includes carcinoid tumor (n = 4), adenosquamous carcinoma (n = 4), sarcomatoid carcinoma (n = 2), undefined NSCLC (n = 3), and mixed NSCLC and small cell lung cancer (n = 1).